预约演示
Beleaguered Theravance logs head-to-head trial loss for Yupelri against Boehringer's Spiriva
2024-01-05
临床2期财报临床失败临床3期临床终止
Theravance has been heavily focused on completing the PIFR-2 head-to-head trial ever since it cut its inhaled Janus kinase (JAK) inhibitor program nezulcitinib back in February of 2023.
When Theravance called it quits on a phase 2 JAK inhibitor program last February, the South San Franciinhaled Janus kinase (JAK)arma company put thnezulcitinibf its chips on a head-to-head trial pitting its Viatris-partnered bronchodilator Yupelri against Boehringer Ingelheim’s Spiriva in chronic obstructive pulmonary disease (COPD).
NearlTheravanceater, that study has played ouJAK inhibitorJAKthough perhaps not in the way Theravance had hoped.ViatrisYupelriBoehringer IngelheimSpirivachronic obstructive pulmonary disease (COPD)
In the phase 4 PIFR-2 study, Theravance and Viatris’ Yupelri, delivered via standard jet nebulizer, failed to demonstrate greater lung function improvement versus Spiriva delivered by a dry powder inhaler, Theravance said Friday.
Theravance plans to roll out additional details from the PIFR-2 study following additional data analyses, he added.
When it comes to Yupelri revenue, Pfizer and Mylan’s generics spinout Viatris records total net sales for the inhalable medicine, of which Theravance is entitled to a 35% share of profits and losses.
For all of 2022, Yupelri brought hPfizertal sMylanof $202.1 million, uViatristhe $161.9 million it garnered the year before. Theravance andTheravanceave yet to publish full-year financial results for 2023.
Theravance has beYupelriily focused on completing the PIFR-2 head-to-head trial ever since it cut its inhaled Janus kinase (JTheravancetor pViatrisnezulcitinib back in February of 2023. The therapy had been in phase 2 development for acute and chronic lung inflammation and fibrotic disease.
At the same time, Theravance said it hoped to prop up a new study of its pipeline asset ampreloxetine,inhaledhJanus kinase (JAK)ed in a late-stage nezulcitiniblood pressure disorder in spring of 2022.acute and chronic lung inflammation
Friday’s trial flop marks the latest in a series of blows for the company.ampreloxetine
When Theravance announced the termination of its nezulcitinib program last year, the company also disclosed that it had reduced its headcount by 17%. That move came several months after the company laid off 75% of its staff following the phase 3 fail of ampreloxetine in September 2021.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。